Difference between revisions of "Bevacizumab-awwb (Mvasi)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead")
m
Line 8: Line 8:
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 +
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
 +
*[[Adenocarcinoma of unknown primary]]
 +
*[[Anaplastic glioma]]
 
*[[Breast cancer]]
 
*[[Breast cancer]]
−
*[[Central nervous system (CNS) cancer]]
 
 
*[[Cervical cancer]]
 
*[[Cervical cancer]]
 +
*[[Cholangiocarcinoma]]
 
*[[Colon cancer]]
 
*[[Colon cancer]]
 
*[[Esophageal cancer]]
 
*[[Esophageal cancer]]
 
*[[Follicular lymphoma]]
 
*[[Follicular lymphoma]]
−
*[[Hepatobiliary cancer]]
+
*[[Glioblastoma]]
 +
*[[Hepatocellular carcinoma]]
 
*[[Melanoma]]  
 
*[[Melanoma]]  
 +
*[[Mesothelioma]]
 
*[[Neuroendocrine tumors]]
 
*[[Neuroendocrine tumors]]
 
*[[Non-small cell lung cancer]]
 
*[[Non-small cell lung cancer]]
 
*[[Ovarian cancer]]
 
*[[Ovarian cancer]]
 +
*[[Pancreatic NET]]
 
*[[Renal cancer]]
 
*[[Renal cancer]]
 +
*[[Small cell lung cancer]]
 
*[[Soft tissue sarcoma]]  
 
*[[Soft tissue sarcoma]]  
−
*[[Unknown primary]]
+
*[[Testicular cancer]]
 
*[[Uterine cancer]]
 
*[[Uterine cancer]]
 +
*[[Vascular sarcoma]]
 +
</div>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
Line 46: Line 55:
 
[[Category:VEGF inhibitors]]
 
[[Category:VEGF inhibitors]]
  
 +
[[Category:Adenocarcinoma of unknown primary medications]]
 +
[[Category:Anaplastic glioma medications]]
 
[[Category:Breast cancer medications]]
 
[[Category:Breast cancer medications]]
−
[[Category:Cancer of unknown primary medications]]
 
−
[[Category:Central nervous system (CNS) cancer medications]]
 
 
[[Category:Cervical cancer medications]]
 
[[Category:Cervical cancer medications]]
 +
[[Category:Cholangiocarcinoma medications]]
 
[[Category:Colon cancer medications]]
 
[[Category:Colon cancer medications]]
 
[[Category:Esophageal cancer medications]]
 
[[Category:Esophageal cancer medications]]
 
[[Category:Follicular lymphoma medications]]
 
[[Category:Follicular lymphoma medications]]
−
[[Category:Hepatobiliary cancer medications]]
+
[[Category:Glioblastoma medications]]
 +
[[Category:Hepatocellular carcinoma medications]]
 
[[Category:Melanoma medications]]  
 
[[Category:Melanoma medications]]  
 +
[[Category:Mesothelioma medications]]
 
[[Category:Neuroendocrine tumor medications]]
 
[[Category:Neuroendocrine tumor medications]]
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Ovarian cancer medications]]
 
[[Category:Ovarian cancer medications]]
 +
[[Category:Pancreatic NET medications]]
 
[[Category:Renal cancer medications]]
 
[[Category:Renal cancer medications]]
 +
[[Category:Small cell lung cancer medications]]
 
[[Category:Soft tissue sarcoma medications]]  
 
[[Category:Soft tissue sarcoma medications]]  
 +
[[Category:Testicular cancer medications]]
 
[[Category:Uterine cancer medications]]
 
[[Category:Uterine cancer medications]]
 +
[[Category:Vascular sarcoma medications]]
  
 
[[Category:Drugs FDA approved in 2017]]
 
[[Category:Drugs FDA approved in 2017]]
 
[[Category:Biosimilars]]
 
[[Category:Biosimilars]]

Revision as of 02:57, 28 January 2018

Note: this is the first FDA-approved biosimilar. The information below is reproduced from the Bevacizumab (Avastin) page, except for the details of FDA indication.

General information

Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

History of changes in FDA indication

  • 9/14/2017: FDA approved for the treatment of patients with the following cancers:
    • Metastatic colorectal cancer, in combination with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment.
    • Mvasi is not indicated for the adjuvant treatment of surgically resected colorectal cancer.
    • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrmidine-oxaliplatin-based chemotherapy for the second-line treatment of patients who have progressed on a first-line bevacizumab product-containing regimen.
    • Non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease.
    • Glioblastoma with progressive disease following prior therapy, based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with bevacizumab products.
    • Metastatic renal cell carcinoma, in combination with interferon alfa.
    • Cervical cancer that is persistent, recurrent, or metastatic disease, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
    • Note: Bevacizumab (Avastin) has a label for ovarian cancer, which was not included in the initial FDA approval for bevacizumab-awwb.

Also known as

  • Brand name: Mvasi
Retrieved from "https://hemonc.org/w/index.php?title=Bevacizumab-awwb_(Mvasi)&oldid=23777"